Temporal genomic heterogeneity guiding individualized therapy in recurrent non-small cell lung cancer
Open Access
- 12 July 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1116809
Abstract
Introduction: Despite the benefit of adjuvant systemic therapy for patients with resected non-small cell lung cancer (NSCLC), the risk of postoperative recurrence remains high. Our objective was to characterize temporal genetic heterogeneity between primary resected and recurrent tumors, and its impact on treatment outcomes.Methods: In this study, next-generation sequencing (NGS) testing was performed on tissue specimens and circulating tumor DNA (ctDNA) collected at postoperative recurrence, and results were compared to the genotypes of initial surgical specimens.Results: Of forty-five patients with matched primary and post-operative recurrent tumors, EGFR status switched in 17 patients (37.8%) at post-operative recurrence and 28 patients (62.2%) had no genotype change (17 mutant, 11 wild-type). Based on the changes of EGFR status, patients were divided into 4 groups. Following subsequent treatment with EGFR TKI o chemotherapy: In group A, with sustained sensitive mutation, the percentage achieving partial response (PR) was the highest, at 72.2%, the median progression-free survival (PFS) was 17 months, and the median overall survival (OS) was 44.0 months respectively; In group B, with genotype changed from wild-type to mutant, 50% achieved PR, PFS was 10 months, and OS was 35 months; In group C, in which mutant status shifted to wild-type or new co-mutation emerged, the percentage achieving PR was 30%, PFS was 9 months, and OS was 35 months. In group D, with sustained wild type, the percentage achieving PR was 27.3%, PFS was 8 months, and OS was 22 months.Discussion: Genotypic shift between paired primary and post-operative recurrent tumors was not infrequent, and this temporal genomic heterogeneity substantially impacted subsequent treatment outcomes.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 30 references indexed in Scilit:
- Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJournal of Thoracic Oncology, 2015
- Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature reviewJournal of Experimental & Clinical Cancer Research, 2015
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsJournal of Clinical Oncology, 2015
- Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancerSurgery Today, 2015
- Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLCJournal of Thoracic Oncology, 2015
- Comparison of Next-Generation Sequencing and Mutation-Specific Platforms in Clinical PracticeAmerican Journal of Clinical Pathology, 2015
- Meta-analysis of Epidermal Growth Factor Receptor and KRAS Gene Status between Primary and Corresponding Metastatic Tumours of Non-small Cell Lung CancerClinical Oncology, 2015
- The ErbB/HER family of protein-tyrosine kinases and cancerPharmacological Research, 2014
- Intratumor Heterogeneity: Seeing the Wood for the TreesScience Translational Medicine, 2012
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009